GC Biopharma Applies For US FDA Fast Track Designation For Sanfilippo Syndrome Treatment
GC Biopharma, led by CEO Eun-cheol Heo, has applied for Fast Track Designation from the U.S. Food and Drug Administration (FDA) for 'GC1130A', a treatment for S...
- Medytox "Myasthenia Gravis Treatment 'MT122', National New Drug Development Project Selection"
- GC Biopharma's 'GC FLU' Vaccine, Awarding $10 Million Worth Of Order From GPO In Thai
- Following the US FDA, Lilly Pharma Declares Samsung BioLogics' Data Management Issues.
- GC Biopharma, Application For Product Permission For The World's First 'Recombinant Protein Anthrax Vaccine'